GlassScriptPhysician profile
Angela May Harmon
NPI 1619440070
$2,795.65
in general payments reported to CMS, 2019-2025
20 companies · $531 in 2025
The $531 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $374 · 2022: $455 · 2023: $545 · 2024: $891 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,155.87 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $298.09 | 2021-2025 | Xifaxan |
| Corcept Therapeutics | $251.59 | 2024-2025 | Korlym |
| Novo Nordisk INC | $169.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $161.10 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $157.06 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $99.64 | 2022-2025 | |
| Amgen INC. | $78.36 | 2022-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $75.84 | 2025 | Rexulti |
| Medtronic, INC. | $74.90 | 2024 | Minimed 780g |
| Biohaven Pharmaceuticals, INC. | $48.11 | 2021 | |
| Exact Sciences Corporation | $41.64 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $32.17 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Lundbeck LLC | $29.96 | 2023 | Vyepti |
| Axsome Therapeutics, INC. | $29.54 | 2024 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29.25 | 2021-2024 | Veozah |
| Viatris Specialty LLC | $21.50 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $15.57 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.68 | 2022 | |
| Dexcom, INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.